<DOC>
	<DOCNO>NCT02799030</DOCNO>
	<brief_summary>This placebo control , double blind , randomize phase II dose-response study evaluate efficacy safety BF-200 ALA ( contain active ingredient 5 - aminolevulinic acid- ALA ) use photodynamic therapy ( PDT ) patient actinic keratosis ( AK ) .</brief_summary>
	<brief_title>A Clinical Trial Topical Photodynamic Therapy With 5-aminolevulinic Acid Treatment Actinic Keratosis</brief_title>
	<detailed_description>The study perform define effective therapeutic dose active pharmaceutical ingredient ( ALA ) nanoemulsion formulation treatment actinic keratosis ( AK ) topical PDT ass efficacy topical PDT new nanoemulsion formulation ALA treatment AK . The efficacy BF-200 ALA calculate AK clearance rate , define proportion AK lesion show complete remission 12 week PDT treatment . Subjects two study centre provide plasma urine sample quantification ALA metabolite , active photosensitizer protoporphyrin IX ( PpIX ) .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>The subject willing able sign inform consent form . Men woman age 18 85 year . Had general good stable health condition confirm physical examination medical history . The subject accept abstain sunbathe solarium study . The subject least 3 10 clinically confirm AK target lesion mild moderate intensity within face bald scalp ( exclude eyelid , lip mucosa ) , i.e . AK grade I II . Grade I AK lesion present flat , pink macula without sign hyperkeratosis erythema . The AK lesion discrete quantifiable ; distance one lesion neighbour lesion great 1.5 cm . The diameter AK lesion le 0.5 cm great 1.5 cm . The subject free significant physical abnormality ( e.g. , tattoo , dermatosis ) potential treatment area could cause difficulty examination final evaluation . The subject willing stop use moisturizers topical treatment antiaging product , vitamin A , vitamin C , and/or vitamin E contain ointment cream , green tea preparation study within treatment area . Sunscreens allow , apply treatment area within approximately 24 hour clinic visit lesion count . Only woman childbearing potential use highly effective method contraception negative serum pregnancy test allow participate study . Had know hypersensitivity ALA. Had receive medication know affect AK 3 month study . Were immunosuppressive therapy . Suffered porphyria . Showed hypersensitivity porphyrin . Suffered photodermatoses . Had inherit acquire coagulation defect . Received medication hypericin systemically act drug phototoxic photoallergic potential within 8 week prior treatment study drug PDT Had evidence clinically significant , unstable medical condition metastatic tumour tumour high probability metastatic spread cardiovascular ( NYHA class III , IV ) immunosuppressive haematological , hepatic , renal , neurological , endocrine collagenvascular gastrointestinal . Subjects clinically stable medical condition include , limited following disease allow include study , medication take treatment disease match criterion exclude disallowed medication list point 11 12 : control hypertension diabetes mellitus type II hypercholesterinaemia osteoarthritis Had currently malignant benign tumour skin within treatment area ( e.g. , malignant melanoma , basal cell carcinoma , squamous cell carcinoma ) . Had receive follow treatment indication treatment area within designated time period PDT treatment ALA : Topical steroid 4 week Topical retinoids 6 week Topical diclofenac preparation 6 week Topical 5fluorouracil preparation 6 week Topical immunomodulators 6 week Surgical excision ( except biopsy diagnostic confirmation ) 6 week Curettage 4 week Cryo , thermo chemodestruction 6 week PDT 6 week Therapeutic UVRadiation 6 week Had receive follow systemic treatment within designated period PDT treatment ALA : Interferon 6 week Immunomodulators immunosuppressive therapy 10 week Cytotoxic drug 6 month Investigational drug 8 week Drugs known major organ toxicity 8 week Corticosteroids ( oral injectable ) 6 week Inhaled corticosteroid ( &gt; 1200 µg/day beclomethasone , &gt; 600 µg/day fluticasone ) 4 week A previous treatment ALA . Known allergy polysorbate 80 , caprylic/capric acid triglyceride , isopropyl alcohol , disodium phosphate dihydrate , sodium hydroxide , hydrochloric acid , propylene glycol , methyl parahydroxybenzoate , propyl parahydroxybenzoate . Were know pregnant lactating ( currently within past 3 month ) . Had dermatological disease treatment area surround area might exacerbate treatment topical ALA cause difficulty examination ( e.g . psoriasis , eczema ) . Show cornu cutaneum like alteration skin face bald scalp ( target area ) . Were currently within past 8 week participate another clinical study . Had active chemical dependency alcoholism assess investigator . Topical steroid treatment dermatological disease ( e.g . atopic dermatitis , lichen planus ) location treatment area allow study provide amount use exceed 2 mg fluorinated steroid daily 1 week 6 mg beclomethasone 1 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>